Key result
Plasma cMyBP-C levels are elevated in pediatric heart failure and track with ROSS severity.
Why the study?
The value of plasma levels of cardiac myosin-binding protein C as a diagnostic and prognostic biomarker in pediatric heart failure was not established.
Does the plasma level of cardiac myosin-binding protein C (cMyBP-C) correlate with the diagnosis and severity of heart failure in pediatric patients?
Case-Control (n=65)
No
Does the plasma level of cardiac myosin-binding protein C (cMyBP-C) correlate with the diagnosis and severity of heart failure in pediatric patients?
Answers are grounded in this paper and cite their sources.
Plasma cMyBP-C levels are significantly elevated in pediatric heart failure patients and correlate with disease severity as measured by the ROSS classification.
ObjectiveTo study the value of measuring plasma levels of cardiac myosin-binding protein C (cMyBP-C) as a biomarker in the diagnosis and prognosis of heart failure (HF) in pediatric patients.BackgroundPrevious research studies have declared that cMyBP-C phosphorylation modulates cardiac contractility. It is a thick filament-associated protein which regulates actin–myosin interaction and thereby the systolic and diastolic function of the heart and regulates cardiac contractility. CMyBP-C has been reported in many studies as a specific early diagnostic biomarker of myocardial infarction.Patients and methodsTo reach the goal of this research, a case–control study was designed. The study sample included 35 Egyptian children from the hospitalized children at Menoufia University Hospital with HF as 'a patient group' and 30 apparently healthy children of similar age and sex matched as 'a control group.'ResultsWe found a significant increase in cMyBP-C (P = 0.001) in the patients with HF. There was a statistically significant difference between cMyBP-C in the patients at admission and their ROSS classification, as higher level was noticed in class IV in relation to classes II and III (P = 0.001), and also higher in class III in relation to class II (P = 0.0.008).ConclusionOur study reveals that the plasma level of cMyBP-C is a significant biomarker, which can be used for diagnosis and prognosis of HF in pediatric patients.
No takes yet. Share an insight, caveat, or question.
Ghani et al. (2021) conducted a case-control in Heart failure in pediatric patients (n=65). Plasma levels of cardiac myosin-binding protein C (cMyBP-C) vs. Healthy children was evaluated on Plasma levels of cMyBP-C (p=0.001). Plasma levels of cMyBP-C were higher in pediatric patients with heart failure compared to healthy controls and increased with higher ROSS classification severity.
Synapse has enriched 10 related papers. Consider them for comparative context: